Q-omics provides the consensus-scored KCTD11 profile across patient tissues and cancer cell-line models. KCTD11 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, KCTD11 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, KCTD11 RNA expression shows 19,551 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight HNSC, KIRC, and KIRP as cancer lineages where KCTD11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCTD11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCTD11 survival associations across molecular data types. KCTD11 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCTD11 RNA expression–survival associations across cancer types. High KCTD11 expression shows unfavorable associations in HNSC, UVM, OV, KICH and BLCA, but favorable associations in ACC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for KCTD11 RNA expression.
This table summarizes KCTD11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for KCTD11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCTD11 shows lower tumor expression in KICH and higher tumor expression in KIRC, KIRP, LIHC, CHOL and HNSC. The KIRC box plot shows higher KCTD11 RNA expression in tumor versus normal tissue (log2 FC = +1.107, t-test p < 0.001).
This table shows molecular features associated with KCTD11 in patient tissues and cancer cell lines. In patient samples, KCTD11 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, KCTD11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and CNS.
